Borje Andersson

Chief Medical Officer / Race Oncology

Professor Borje Andersson was initially engaged as a scientific and clinical consultant to Race Oncology in January 2019, before becoming chair of its clinical advisory board in December 2019 and chief medical officer in October 2020.

Prof Andersson is a research leader in the field of leukaemia and stem cell transplantation at the MD Anderson Cancer Center in Houston, Texas. He is the inventor of IV Busulfan, an FDA-approved drug used in stem cell transplantation.

Lists and Charts

Roles

2020

Chief Medical Officer

Race Oncology

Year started and most recent title

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
265^th	Objective Corporation">Objective Corporation	55.8%	25.08%
266^th	Metals X">Metals X	55.66%	29.82%
267^th	Race Oncology">Race Oncology	55.55%	49.18%
268^th	K&S Freighters">K&S Freighters	55.35%	24.09%
269^th	Aurelia Metals">Aurelia Metals	54.6%	-15.33%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

Person Activity

	NEW ROLE: Chief Medical Officer, Race Oncology	16 Apr 2021
	NEW ROLE: Executive Director, Race Oncology	03 Nov 2020

Related Information

Access to our data for Borje Andersson is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Borje Andersson is linked to 2 organisations which are included in 1 list - Public Companies - non WA.

To see the data you will need to Subscribe.